| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg | |||
| 100mg | |||
| Other Sizes |
| Targets |
Akt2 (IC50 = 17 nM); p70S6K (IC50 = 85 nM); Akt1 (IC50 = 32 nM); Akt3 (IC50 = 47 nM); PKA (IC50 = 20 nM)
AT7867 targets Akt1, Akt2, Akt3, p70S6K, and PKA. It is a potent ATP-competitive inhibitor with IC50s of 32 nM (Akt1), 17 nM (Akt2), 47 nM (Akt3), 85 nM (p70S6K), and 20 nM (PKA). |
|---|---|
| ln Vitro |
The inhibition of AKT2 by AT7867 is shown to be ATP-competitive with a Ki of 18nM.Additionally, AT7867 exhibits strong activity against the structurally related AGC kinases p70S6K and PKA, but exhibits a distinct window of selectivity when it comes to kinases from other kinase subfamilies. Studies on the inhibition of in vitro growth demonstrate that AT7867 inhibits proliferation in a number of human cancer cell lines. Inhibiting proliferation with AT7867 appears to be most effective in the MES-SA uterine, MDA-MB-468 and MCF-7 breast, HCT116 and HT29 colon, and MDA-MB-468 and MCF-7 cell lines (IC50 values range from 0.9 to 3 M), and least effective in the two prostate cell lines (IC50 values range from 10 to 12 μM) [1].
In vitro, AT7867 suppresses Akt activity by inhibiting the phosphorylation of GSK-3β in human tumor cells with an IC50 of 2-4 μM. It also induces the phosphorylation of Akt direct substrates, including the transcription factors FKHR (FoxO1a) and FKHRL1 (FoxO3a). |
| ln Vivo |
Following oral administration at 20 mg/kg, the elimination of AT7867 from plasma appears to be similar to that observed after i.v. administration. Following an oral dose of 20 mg/kg of AT7867, plasma levels stay above 0.5 M for at least 6 hours. The bioavailability through the oral route is calculated to be 44% under the assumption that linear pharmacokinetics occur after intravenous administration. Therefore, this model is used for in vivo pharmacodynamic (PD) biomarker studies. Athymic mice with MES-SA tumors are given doses of AT7867 (90 mg/kg p.o. or 20 mg/kg i.p.) after pharmacokinetic and tolerability studies, and the phosphorylation status of GSK3β and S6RP in tumors is tracked over time.
In vivo, AT7867 is an orally active compound. As an inhibitor of the PI3K/AKT/mTOR pathway, it has potential antitumor activity. Specific in vivo models and efficacy data are not detailed in the available literature. |
| Enzyme Assay |
The radiometric filter binding method is used for the kinase assays for AKT2, PKA, p70S6K, and CDK2/cyclinA. In the compound's presence, assay reactions are set up. For AKT2, the AKT2 enzyme is incubated for 4 hours with 25 μM AKTide-2T peptide (HARKRERTYSFGHHA), 20 mM MOPS, pH 7.2, 5 mM EDTA, 15 mM MgCl2, 1 mM sodium orthovanadate, 1 mM DTT, 10 μg/mL BSA, and 30 μM ATP (1.16 Ci/mmol). For the PKA assay, the PKA enzyme and 50 μM peptide (GRTGRRNSI) are incubated for 20 minutes in a solution containing 2 mM MOPS, pH 7.2, 25 mM β-glycerophosphate, 5 mM EDTA, 15 mM MgCl2, 1 mM orthovanadate, 1 mM DTT, and 40 μM ATP (0.88 Ci/mmol). For CDK2, the CDK2/cyclinA enzyme and 0.12 g/ml histone H1 are incubated for 4 hours in 20 mM MOPS, pH 7.2, 25 mM -β-glycerophosphate, 5 mM EDTA, 15 mM MgCl2, 1 mM sodium orthovanadate, 1 mM DTT, and 0.1 mg/ml BSA and 45 μM ATP (0.78 Ci/mmol). Orthophosphoric acid is used to stop assay reactions, and the stopped reaction mixture is then transferred to Millipore MAPH filter plates where it is filtered. After washing the plates and adding scintillant, the radioactivity is then determined using scintillation counting on a Packard TopCount. IC50 values are computed using the GraphPad Prism software from replicate curves. All other enzyme assays are carried out in addition to AKT1 and 3 assays[1].
The inhibitory activity of AT7867 is determined using standard kinase assays. These cell-free assays measure the compound's ability to inhibit the phosphorylation activity of purified kinases (Akt1/2/3, p70S6K, PKA). |
| Cell Assay |
Before being treated with AT7867, cells are grown for 24 hours in 10% FBS-supplemented medium in 96-well microplates at a density of 16,000 cells per well. For an hour, the cells receive AT7867 or vehicle control. After that, cells are fixed with 3% paraformaldehyde, 0.25% glutaraldehyde, and 0.25% Triton-X100, washed, and blocked with 5% milk in tris-buffered saline with 0.1% Tween-20 (TBST) before being incubated with a phospho-GSK3 (serine 9) antibody overnight. The plates are then washed, a secondary antibody is added, and DELFIA reagents are used to enhance the signal. Using non-linear regression analysis and a sigmoidal dose-response (variable slope) equation, the IC50 value for each inhibitor is determined in GraphPad Prism after normalizing the europium counts to the protein concentration[1].
The cellular activity of AT7867 is assessed by measuring its effects on downstream signaling pathways. This includes measuring the phosphorylation of GSK-3β and other Akt substrates in human tumor cell lines, such as U87MG cells. |
| Animal Protocol |
Mice: The intravenous and oral doses are prepared in a solution containing 5% ethanol, 100% PG, 5% CremophorEL, and 80% PBS for pharmacokinetic studies. The formulation for the subcutaneous dose is 10% PG and 25% (20%, v/v) Solutol. Prior to MELK-8a analysis, plasma samples are collected at predetermined intervals and kept frozen (20 °C). MELK-8a drug levels in plasma are quantified using an LC-MS/MS technique[1]. A standard calibration line made with AT7867 is used to quantify sample extracts, and an inhibitor-specific liquid chromatography tandem mass spectrometry (LC-MS/MS) technique is used for this. The parameters of pharmacokinetics are established.
Specific in vivo animal models are not detailed. Given its mechanism, relevant models would include murine xenograft models of various cancers to study its antitumor efficacy as a single agent or in combination with other therapies. |
| ADME/Pharmacokinetics |
AT7867 dihydrochloride is an orally active compound. Its pharmacokinetic properties, such as oral bioavailability and half-life, would be characteristic of a small molecule designed for oral administration, although specific parameters are not detailed in the available literature.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for AT7867 is not provided. As a kinase inhibitor, its safety profile would be a critical aspect of its development. Standard toxicological studies would be required to assess its safety for potential therapeutic applications.
|
| References | |
| Additional Infomation |
AT7867 is a research tool for studying the PI3K/AKT/mTOR signaling pathway. Its ability to inhibit both Akt and p70S6K makes it a valuable compound for investigating the role of these kinases in cancer and for validating them as therapeutic targets.
|
| Molecular Formula |
C20H22CL3N3
|
|---|---|
| Molecular Weight |
410.7678
|
| Exact Mass |
409.087
|
| Elemental Analysis |
C, 58.48; H, 5.40; Cl, 25.89; N, 10.23
|
| CAS # |
1431697-86-7
|
| Related CAS # |
AT7867;857531-00-1
|
| PubChem CID |
71576653
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
26
|
| Complexity |
394
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ClC1C([H])=C([H])C(=C([H])C=1[H])C1(C2C([H])=C([H])C(C3C([H])=NN([H])C=3[H])=C([H])C=2[H])C([H])([H])C([H])([H])N([H])C([H])([H])C1([H])[H].Cl[H].Cl[H]
|
| InChi Key |
ICUAUJBVBVIUAE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H20ClN3.2ClH/c21-19-7-5-18(6-8-19)20(9-11-22-12-10-20)17-3-1-15(2-4-17)16-13-23-24-14-16/h1-8,13-14,22H,9-12H2,(H,23,24)2*1H
|
| Chemical Name |
4-(4-chlorophenyl)-4-[4-(1H-pyrazol-4-yl)phenyl]piperidine;dihydrochloride
|
| Synonyms |
AT7867 Dihydrochloride; AT-7867 Dihydrochloride; AT 7867 Dihydrochloride
|
| HS Tariff Code |
2934.99.03.00
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: ~2.3 mg/mL (~5.5 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 3.25 mg/mL (7.91 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 32.5 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 3.25 mg/mL (7.91 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 32.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 3.25 mg/mL (7.91 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4345 mL | 12.1723 mL | 24.3445 mL | |
| 5 mM | 0.4869 mL | 2.4345 mL | 4.8689 mL | |
| 10 mM | 0.2434 mL | 1.2172 mL | 2.4345 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
